



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 31 Jan 2020 (#5)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

**Tygerberg Campus:** [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • **Stellenbosch Campus** [lizek@sun.ac.za](mailto:lizek@sun.ac.za)

## Important Notice

- **[NOT-HL-19-747](#) Request for Information (RFI): Interest in data and specimens from the Hemophilia Growth and Development Study (HGDS) for research on HIV-associated comorbidities, coinfections and complications.** This Notice is a time-sensitive Request for Information (RFI) inviting comments on potential interest in data and specimens from the Hemophilia Growth and Development Study (HGDS) repository for research on HIV-associated comorbidities, coinfections and complications, especially in heart, lung, blood and sleep (HLBS), as well as suggestions or ideas on how investigators may want to use the data and specimens from the cohort for what kind of research.

### 1. International Research Ethics Education and Curriculum Development Award (masters level programs) (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-19-244](#)

**Type:** R25

**Application Due Date:** June 4, 2020, June 4, 2021. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that foster a better understanding of biomedical, behavioral and clinical research and its implications.

- **Courses for Skills Development**
- **Mentoring Activities**
- **Curriculum or Methods Development**

The goal of this initiative is to support educational activities that foster a better understanding of the ethics of international biomedical, behavioral and clinical research and enhance the application of research ethics principles in low- and middle-income countries (LMICs). This program aims to increase the number of LMIC research intensive institutions that can provide advanced education in international research ethics. Education programs supported by this initiative will equip scientists, health professionals and academics in these countries with in-depth knowledge of the ethical principles, processes and policies related to international clinical and public health research. Programs should be designed to strengthen the critical competencies needed to provide research ethics education, ethical review leadership and expert consultation to LMIC researchers, their institutions, governments and international research organizations. To accomplish this goal, this FOA will support innovative LMIC masters level research ethics education programs proposing integrated activities to develop curriculum, courses for skills development, including practicum experiences, and creative mentoring approaches. Applications may be submitted by U.S., HIC or LMIC research intensive institutions, however, all applications from U.S. or other HIC institutions must include a collaborating institution from a LMIC

**Budget:** Applications may request up to \$230,000 direct costs per year. The total project period may not exceed 5 years.

### 2. International Bioethics Research Training Program (doctoral/postdoctoral level programs) (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-19-243](#)

**Type:** D43

**Application Due Date:** June 4, 2020, June 4, 2021. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The overall goal of this initiative is to support the development of a sustainable critical mass of bioethics scholars in low and middle-income country (LMIC) research intensive institutions with the capabilities to conduct original empirical or conceptual ethics research that addresses challenging issues in health research and research policy in these countries as well as provide research ethics leadership to their institutions, governments and international research organizations. FIC will support LMIC-U.S. collaborative institutional bioethics doctoral and postdoctoral research training programs that incorporate didactic, mentored research and training components to prepare multiple individuals with ethics expertise for positions of scholarship and leadership in health research institutions in the LMIC. This Funding Opportunity Announcement (FOA) allows support of trainees as the lead investigator of an independent clinical trial; or a separate ancillary study to an existing trial; or to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

**Budget:** Applicants may request up to \$230,000 direct costs per year. The total project period for an application submitted in response to this funding opportunity may not exceed 5 years.

### 3. Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-19-283](#)

**Type:** D43

**Application Due Date:** August 20, 2020; August 20, 2021. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications for research training programs to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to conduct HIV research relevant to the evolving HIV epidemic in their country. This FOA can support training for conducting research in a broad range of HIV research areas across HIV prevention, treatment, care, and quality of life continuum. This includes basic, epidemiologic, clinical, behavioral and social sciences, community-based, implementation, operations, health services, and health systems research. Cross-disciplinary research as well as HIV associated comorbidities and coinfections affecting the HIV epidemic will be supported under this FOA. An application should focus the proposed training program to strengthen research capacity in a defined HIV scientific area at a specific LMIC institution and collaborating LMIC partner institutions. This FOA allows qualified Trainees to serve as the lead investigator of an independent clinical trial; or to propose a separate ancillary study to an existing trial under the mentorship of an appropriate clinical researcher or to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

**Budget:** Application budgets are limited to \$280,000 in direct costs per year exclusive of consortium indirect costs. The maximum project period is 5 years.

### 4. Planning Grant for Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR -19-284](#)

**Type:** D71

**Application Due Date:** [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The Fogarty HIV Research Training Program supports research training that strengthens HIV research capacity of institutions in low-and middle-income countries (LMICs). This FOA offers an opportunity for LMIC institutions to submit a planning grant application to prepare to participate in the Fogarty HIV Research Training Program. These applications must propose a plan to develop a research training program and the subsequent application that will be submitted in response to the companion D43 FOA (PAR-19-283). The planned research training program should strengthen research capacity in a defined high priority HIV scientific area (NOT-OD-15-137) at an LMIC institution(s).

**Budget:** Application budgets are limited to \$28,000 direct costs per year exclusive of consortium indirect costs. The maximum project period is 2 years.

### 5. Infrastructure Development Training Programs for Critical HIV Research at Low-and Middle-Income Country Institutions (Clinical Trials Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-19-285](#)

**Type:** G11

**Application Due Date:** August 20, 2020, August 20, 2021. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The overall goal of the Fogarty HIV Research Training Program (HIVRT) is to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to conduct HIV research on the evolving HIV epidemic in their countries. This Funding Opportunity Announcement (FOA) encourages collaborative applications from U.S. and LMIC institutions to develop training programs to achieve technical, administrative and financial management expertise required for one of several research infrastructure support functions considered critical to a successful high-quality research environment. These are: a) research administration and management, b) research integrity oversight, c) ethical review of research for the protection of human subjects, d) laboratory animal welfare oversight, e) health sciences library and information services, f) information and communications technology systems (ICT) for research, g) biostatistics and data analysis, h) technology transfer and intellectual property protection, and i) any area not mentioned above that justifiably will contribute to enhancing Institutional services that can support research activities. Research infrastructure support training programs will maximize previous investments, further strengthen the LMIC institution's research capabilities, and provide more accessible research infrastructure training opportunities to others in their own country and in other LMICs.

**Budget:** Application budgets are limited to \$94,000 direct costs per year exclusive of consortium indirect costs. Indirect Costs (also known as Facilities & Administrative [F&A] Costs) are reimbursed at 8% of modified total direct costs (exclusive of tuition and fees, consortium costs in excess of \$25,000, and expenditures for equipment), rather than on the basis of a negotiated rate agreement. The Indirect Cost limitation applies to direct awards and to subcontracts. The maximum project period is 3 years.

### 6. Mobile Health: Technology and Outcomes in Low and Middle Income Countries (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-19-376](#)

**Type:** R21/R33

**Application Due Date:** Dec 3, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory/developmental research applications that propose to study the development, validation, feasibility, and effectiveness of innovative mobile health (mHealth) interventions or tools specifically suited for low- and middle-income countries (LMICs) that utilize new or emerging technology, platforms, systems, or analytics. The overall goal of the program is to catalyze innovation through multidisciplinary research that addresses global health problems, develop an evidence base for the use of mHealth technology to improve clinical and public health outcomes, and strengthen mHealth research capacity in LMICs. Applicants are required to propose partnerships between at least one U.S. institution and one LMIC institution. This FOA provides support for up to two years (R21 phase) for technology development and feasibility studies, followed by a possible transition to expanded research support (R33 phase) for validation, larger-

scale feasibility, and effectiveness studies. Transition to the R33 depends on the completion of applicant-defined milestones, as well as program priorities and the availability of funds. All applicants must address both the R21 and R33 phases.

**Budget:** The R21 phase may not exceed \$125,000 in direct costs in any single year of the R21 phase. The R33 phase may not exceed \$200,000 in direct costs in any single year of the R33 phase. The project period is limited to 2 years for the R21 phase and up to 3 years for the R33 phase. The total project period may not exceed 5 years.

**Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University**  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

**Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University**  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 03 Feb 2020 (#6)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Important Notice

- **NOT-OD-20-062: Findings of Research Misconduct:** ORI found that Respondent engaged in research misconduct by knowingly, intentionally, and/or recklessly falsifying data included in the following one (1) paper and two (2) grant applications.
- **NOT-AA-20-002: Notice of National Institute on Alcohol Abuse and Alcoholism (NIAAA) Participation in “Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (D43 Clinical Trial Optional).**
- **NOT-EB-20-001: National Institute of Biomedical Imaging and Bioengineering (NIBIB) Plans to Announce a Prize Competition: NIH Technology Accelerator Challenge: Non-invasive Diagnostic Technologies for Global Health.** The National Institutes of Health (NIH) is supporting the bioengineering competition to spur the design and development of non-invasive, handheld, digital diagnostic devices that will target anemia, sickle cell disease, malaria, and other blood-related diseases. This Notice is being provided to allow potential entrants sufficient time to form multidisciplinary teams to develop innovative solutions to submit to the competition. The Announcement is expected to be published February 2020 with an expected submission window from March 2, 2020 through July 2, 2020. NIBIB intends to award cash prizes for the challenge competition. In addition, the Bill & Melinda Gates Foundation will consider winners and honorable mentions identified through this challenge for potential follow-on support to accelerate development of the proposed device for global health settings. Participants will present a design and initial feasibility data or references for a non-invasive diagnostic platform to address two diseases in the vasculature (at least one of which must be sickle cell, malaria, or anemia). The technology design must describe both the biological principle of the test and measurement approach. Participants may share data collected on prototypes (if available) and evidence or feasibility data that de-risk elements of the test and the device. In addition, participants should present a description of the path for translation of the technology to global health use cases and how the technology will need to develop further to reduce cost and be suitable for field use. The challenge announcement will be posted on [www.Challenge.gov](http://www.Challenge.gov) and <https://venturewell.org/ntac> websites.

### 1. International Research in Infectious Diseases (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-20-108](#)

**Type:** R01

**Application Due Date:** July 15, 2020; July 15, 2021; July 15 2022 AIDS dates: August 19, 2020; August 19, 2021; August 19, 2022. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of high-priority, regionally relevant infectious disease research by international investigators in resource-constrained countries. Applicant organizations must be headquartered in foreign (non-U.S.) resource-constrained countries (i.e. low-income economies, lower-middle-income economies, and upper-middle-income economies by [World Bank Classification](#)). Eligibility status of applicant organizations will be determined by this World Bank Classification list at application submission date. Research should focus on infectious diseases, including HIV/AIDS, of interest to the local country and important from a global health perspective. Collaborative projects involving investigators from international sites and the U.S. are particularly encouraged. These grants will serve to build independent research capacity by providing direct funding to investigators who do not currently have NIH-funded grant or contract awards for research projects. The intent of these activities is to advance the development of local scientific expertise.

**Budget:** Applications may request a budget of up to \$125,000 per year in direct cost and a maximum of \$625,000 in direct costs over a five-year project period. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Research Development and Support Division (RDS),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

10 Feb 2020 (#7)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply *ASAP*, but not later than **60 days** before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Important Notice

- **2020 NIAID Omnibus Broad Agency Announcement:** Consider submitting a proposal through [HHS-NIH-NIAID-BAA2020-1](#) if you can carry out research supporting program objectives of our [Division of Allergy, Immunology, and Transplantation](#) (DAIT) and [Division of Microbiology and Infectious Diseases](#) (DMID). It contains five (5) distinct Research Areas (RA), each with a specified closing date and time.
  - **DAIT RA 001:** *Development of Radiation/Nuclear Medical Countermeasures (MCMs)* Due 9 Apr 2020
  - **DMID RA 002:** *Advanced Development of Vaccine Candidates for Acute Flaccid Myelitis Associated with Enterovirus D68* Due 28 Feb 2020
  - **DMID RA 003:** *Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases.* Due 9 Apr 2020
  - **DMID RA 004:** *Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases.* Due 9 Apr 2020
  - **DMID RA 005:** *Advanced Development of Diagnostics for Biothreats and Emerging Infectious Diseases.* Due 9 Apr 2020
- **Notice of Special Interest (NOSI):** A Notice of Special Interest (NOSI) is a new format for NIH Institutes/Centers to share and update their research priorities. NOSIs are intended to replace Program Announcements (PAs) that do not have special review criteria or set aside funds. Each NOSI describes aims in a specific scientific area(s) and points to Funding Opportunity Announcements (FOAs) through which investigators can apply for support.
  - **NOT-DA-20-013:** **Notice of Special Interest (NOSI): Drug-drug interactions among substances of abuse, medications to treat HIV infection, and pharmacotherapies to treat substance use disorders.** The purpose of this Notice is to encourage grant applications proposing research to evaluate potential interactions among substances of abuse, medications to treat Substance Use Disorders (SUDs), and medications to treat HIV infection. The aim is to support pre-clinical and clinical research to study the pharmacokinetic (PK), pharmacodynamic (PD), and toxicological interactions among those three groups of substances.
  - **NOT-DA-20-031:** **Notice of Special Interest (NOSI): Transcriptomic, epigenomic, regulatory RNA or functional genomic research in Substance Use Disorders.** The purpose of this Notice is to inform potential applicants to the National Institute on Drug Abuse (NIDA) of special interest in research examining transcriptomic, genomic, epigenomic, regulatory RNA, nuclear organization, or functional genomics to better understand Substance Use Disorder (SUD)-related biological processes.
  - **NOT-HG-20-017:** **Notice of Special Interest: Genomic Data Repositories ([PAR-20-089](#)) and Knowledge bases ([PAR-20-097](#))** The purpose of this NOSI is to communicate NHGRI's special interest in potential applications under the Biomedical Data Repository (PAR-20-089) and Knowledgebase (PAR-20-097) FOAs, focused on the establishment of new, or continued development of established genomic data resources that use state-of-the-art and cost-effective technologies and approaches, and that are of high value to the broad genomic research community.

- **Grant Applicants: A Focus on Facilities and Equipment:** Peer reviewers will consider environment as part of their evaluation, so be sure to give as much detail as possible. Environment includes **two required attachments** in your application a) “*Facilities and other resources*” and b) “*Equipment*”. To see what reviewers will consider, go to our [Review Criteria SOP](#).
- **Five Questions to Answer When Considering Vertebrate Animals Research:** All procedures involving live vertebrate animals must be designed and performed with due consideration of their relevance to human or animal health, the advancement of knowledge, or the good of society.
- **NOT-OD-20-068: FY 2020 Fiscal Policies for Grant Awards: Funding Levels, Salary Limits, and Stipend Levels:**
  - FY 2020 Funding Levels – Non-competing continuation awards made in FY 2020 will generally be issued at the commitment level indicated on the Notice of Award.
  - Next Generation Researchers Initiative Policy – Prioritizing meritorious R01- equivalent applications from early stage investigator (ESI) principal investigators.
  - Salary Limits – Salary limit is set at \$197,300.

**NIH’s All About Grants podcast series: Podcast on Notices of Special Interest (NOSIs)** ([MP3](#) / [Transcript](#)).

**1. International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-20-108](#)

**Type:** R01

**Application Due Date:** July 15, 2020; July 15, 2021; July 15 2022. **AIDS Dates:** August 19, 2020; August 19, 2021; August 19, 2022 Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of high-priority, regionally relevant infectious disease research by international investigators in resource-constrained countries. Applicant organizations must be headquartered in foreign (non-U.S.) resource-constrained countries (i.e. low-income economies, lower-middle-income economies, and upper-middle-income economies by World Bank Classification). Eligibility status of applicant organizations will be determined by this World Bank Classification list at application submission date.

**Budget:** Applications may request a budget of up to \$125,000 per year in direct cost and a maximum of \$625,000 in direct costs over a five-year project period. The maximum project period is 5 years

**2. Molecular Mechanisms of Combination Adjuvants (MMCA) (U01 Clinical Trial Not Allowed)**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-20-004](#)

**Type:** U01

**Application Due Date:** June 29, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) solicits applications that propose studies of the mechanism of action of a combination of two or more vaccine adjuvants (combination adjuvant). Adjuvants that are combined in these studies must already have shown individual immune modulating activity. Understanding the molecular and cellular mechanisms underlying the synergistic enhancement of immune responses by combination adjuvants will facilitate the rational selection of components for vaccines tailored to specific pathogens. The Cooperative Agreement grant mechanism allows for coordination of these research efforts with NIAID’s overall adjuvant research objectives. The long-term goal is to promote the development of novel adjuvant combinations that will improve the immunogenicity of vaccines while limiting or eliminating reactogenicity.

**Budget:** NIAID intends to commit \$3.2 million in FY 2021 to fund 5-6 awards. Application budgets are limited to \$400,000 in Direct Costs per Fiscal Year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105





# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

17 Feb 2020 (#8)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizek@sun.ac.za](mailto:lizek@sun.ac.za)

## Important Notice

- NIH participates in the [Global Alliance for Chronic Diseases \(GACD\)](#), a collection of publicly funded research agencies that supports innovative research collaborations to address the prevention and treatment of chronic diseases in vulnerable populations. The current GACD funding call focuses on implementation research proposals for the primary and secondary prevention of cancer in low- and middle-income countries (LMICs), and in populations facing conditions of vulnerability in high-income countries. NIH funding opportunity supporting this call for applications: [Notice of Special Interest \(NOSI\): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments \(NOT-CA-20-025\)](#). Submit applications using one of the following NIH funding opportunity announcements (FOAs). Applies to application due dates from 5 June 2020 to 8 May 2022.
  - Dissemination and Implementation Research in Health ([R01 Clinical Trial Optional](#)) ([PAR-19-274](#))
  - Dissemination and Implementation Research in Health ([R21 Clinical Trial Optional](#)) ([PAR-19-275](#))
  - Dissemination and Implementation Research in Health ([R03 Clinical Trial Not Allowed](#)) ([PAR-19-276](#))

Proposals must focus on implementation research for the primary and/or secondary prevention of cancer in LMICs and/or in populations facing conditions of vulnerability in HICs. Proposals must build on evidence-based interventions (including cost-effectiveness) for the respective population groups under defined contextual circumstances. Research activities should focus on their implementation in real-life settings. The proposed interventions should be gender-responsive. The aim should be to adapt and scale-up the implementation of these intervention(s) in accessible, affordable and equitable ways in order to improve the prevention and early diagnosis of cancer in real-life settings. Interventions should meet conditions and requirements of the local health and social system context and address any other contextual factors identified as possible barriers.

- [NOT-DK-20-010](#) Notice of Update to Research Priorities of [PAS-18-698](#), High Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional).
- [NOT-DK-20-011](#) Notice of Update to Research Priorities of [PA-18-615](#), Pilot and Feasibility Studies of HIV and Animal Models for HIV Infection within the Mission of NIDDK (R21 Clinical Trial Optional)
- [NOT-TW-20-001](#) Notice of Change to update the Letters of Intent due date for 2020 for the Funding Opportunity Announcement [PAR-20-030](#) HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)
- [NOT-AI-20-032](#) Notice of Intent to Publish a Funding Opportunity Announcement for Martin Delaney Collaboratories for HIV Cure Research (UM1 Clinical Trial Not Allowed). The National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID) intend to publish Funding Opportunity Announcements (FOAs) for the Martin Delaney Collaboratories (MDC) for HIV Cure Research program, a cooperative partnership between academia, industry, government, and community aimed at developing innovative strategies for cure or sustained remission of persistent HIV infection (<https://www.niaid.nih.gov/research/mdc>). Two separate FOA's will be issued: one will be a re-issue of the Martin Delaney Collaboratories for HIV Cure Research (UM1) FOA, and the other will be a new FOA for an

MDC focused specifically on HIV cure research in pediatric populations. Only new applications will be accepted under both FOAs; competitive renewal applications from existing awards will not be accepted. Applications will include both basic and applied (preclinical) research. Some aspect of clinical research must be included, however clinical trials will not be allowed in either FOA. Applicants will be encouraged to develop clinical trial protocols within the collaboration and to seek separate funding for implementation of the trials through NIAID HIV/AIDS Clinical Trial Networks, U01 grant applications, industry sponsorship, or support from other funding organizations. NIAID intends to fund 4-6 awards and intends to cap direct costs at \$3.5 million per year for each award. Estimated Publication Date of Funding Opportunity Announcement: 16 June 2020.

- **[NOT-CA-20-028](#) Notice of Intent to Publish a Funding Opportunity Announcement for Metastasis Research Network (U54 Clinical Trial Not Allowed).** This Notice is being provided to allow potential applicants time to develop responsive projects and meaningful collaborations. The FOA is expected to be published in April 2020. The FOA will use the U54 activity code (Clinical Trial Not Allowed). The purpose of the FOA is to support the development of collaborative, multi-disciplinary basic research centers to elucidate and integrate a mechanistic understanding of the non-linear, dynamic, and emergent processes in metastasis. It is anticipated that each center will use systems-level approaches that encompass chronological progression and biological scales to derive a more comprehensive and cohesive picture of metastasis. Centers may derive new physiologically relevant models that capture the entire metastatic process or develop new experimental and analytical technologies or probes for tracking and monitoring the in vivo dynamics of metastatic cell states. Estimated Publication Date of Funding Opportunity Announcement: 15 April 2020. Estimated Total Funding: Up to \$7.5 million in fiscal year 2021. Expected Number of Awards: Five
- **[NOT-TW-20-002](#) Notice of Intent to Publish a Funding Opportunity Announcement for Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) – Research (U01).** Estimated Publication Date of Funding Opportunity Announcement: 1 July 2020. First Estimated Application Due Date: 4 November 2020. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects in anticipation of the linked FOAs. The overall objective of the Global Environmental and Occupational Health (GEOHealth) program is to support the development of institutions in the Low- or Middle-Income Countries (LMICs) that will serve as regional hubs for collaborative research, data management, training, curriculum and outreach material development, and policy support around high priority local, national, and regional environmental and occupational health threats; and to support a global network of hubs that serves as a platform for coordinated research and training activities in environmental and occupational health. Applicants are encouraged to involve multiple U.S. and LMIC partner institutions in the proposed research project.
  - See the old/ previous FOA's:
    - [RFA-TW-14-001 Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health \(GEOHealth\) – Research \(U01\)](#)
    - [RFA-TW-14-002 Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health \(GEOHealth\) – Research Training \(U2R\).](#)
- **[NOT-AI-20-033](#) Pre-Solicitation Notice: NIAID Specimen Repository.** National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) conducts and supports epidemiological and clinical research on infectious diseases. Many of the large clinical and epidemiological studies funded by NIAID collect biologic specimens from subjects for ongoing and future studies. The collection and storage of these specimens from many different research studies in a single repository is a valuable resource with which researchers can rapidly validate scientific hypotheses and algorithms for clinical decision-making. Comprehensive and well-maintained specimen collections coupled with epidemiologic data have facilitated research on the pathogenesis of HIV disease, development of novel drug approaches, HIV prevention studies of potential microbicides and vaccines, and approaches for eliminating HIV reservoirs". The NIAID Specimen Repository (NSR), first funded in 1988, provides receipt, storage and distribution of biological specimens received from institutions conducting NIAID-sponsored clinical trials and observational cohort studies. Presently the repository largely houses specimens from HIV related clinical trials and cohort studies. The specimens have been collected over many years. Selection of Study Groups storing specimens in the NSR is guided by scientific priorities of NIAID. The current NIAID Study Groups storing specimens in the NSR are: the Women's Interagency HIV Study (WIHS) and the Multicenter AIDS Cohort Study (MACS), now called the MACS/WIHS Combined Cohort Study (MWCCS); and the HIV Vaccine Trials Network (HVTN). The NSR also



maintains specimens from other smaller NIAID-sponsored studies that have been completed. There are currently over 8 million specimens in the NSR. The current contract with Precision Bioservices, Inc., Contract No. HHSN272201400037C, will expire on September 29, 2021. Duration of contract: 7 Years. The purpose of this contract is the short, moderate and long-term specimen storage of domestic and international clinical research specimens through receipt, cryopreservation, and storage of specimens from research sites or laboratories. Specimens include peripheral blood mononuclear cells, serum, plasma, tissue and other bodily fluids or substances such as cervicovaginal lavage (CVL), semen, saliva, urine, feces, autopsy and biopsy materials and whole blood spots dried on filter paper.

- It is anticipated this will be a performance-based acquisition and a cost reimbursement, term/level of effort, type of contract will be awarded.
- This RFP will be available electronically on/about February 20, 2020 and may be accessed through beta.SAM.gov.

- **[NOT-CA-20-025](#) Notice of Special Interest (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments.** The purpose of this Notice is to inform potential applicants of the interest of the National Cancer Institute (NCI) in supporting implementation research related to cancer prevention and control in low- and middle-income countries (LMICs) and in low resource settings. This Notice also aligns with the [Global Alliance for Chronic Diseases](#) (GACD) 2020 Cancer Call. NCI encourages applications that pursue innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines in low-resource settings. The research projects on which these applications will be based should be focused on dissemination and implementation research for the primary and secondary prevention of cancer in LMICs and/or in populations facing conditions of vulnerability in HICs. The projects described in grant applications must be built on evidence-based interventions (including cost-effectiveness) for the respective population groups under defined contextual circumstances. For promising interventions, a limited validation period can be envisaged. However, the core of the research activities should focus on their implementation in real-life settings. NCI is interested in proposed studies to adapt and scale-up the implementation of these interventions in accessible, affordable, and equitable ways in order to improve the prevention and early diagnosis of cancer in real-life settings. Interventions should meet conditions and requirements of the local health and social system context and address any other contextual factors identified as possible barriers. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements through the expiration date of this Notice.

- [PAR-19-274](#): Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
- [PAR-19-275](#): Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
- [PAR-19-276](#): Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)

- **[NOT-MH-20-031](#) Notice of Special Interest to Highlight Research Priorities for Risk Algorithms Applications in Healthcare Settings to Improve Suicide Prevention.** NIMH held a meeting in June 2019 to identify and prioritize research needs in the application of predictive analytics in suicide prevention among healthcare providers. The meeting summary details research topics and gaps that included: biostatistical challenges, provider and patient understanding of risk algorithms, ethical considerations, needs for clinical decision tools to guide risk algorithm application, and policy-relevant research. NIMH is encouraging practice and deployment relevant applications proposed by multidisciplinary teams. This notice applies to due dates on or after 5 June 2020 and subsequent receipt dates through 8 September 2022.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizel*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105